Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone

DISEASE CHARACTERISTICS: * Histologically confirmed Ewing's sarcoma family of tumors or rhabdomyosarcoma with bone metastases * Refractory to conventional therapy OR * Responsive to conventional therapy with osseous metastases at diagnosis that are extensive enough to preclude concurrent radiotherapy to all sites * Soft tissue, pulmonary, and/or bone marrow metastases in addition to cortical bone allowed * Extraosseous sites of disease allowed if amenable to surgical resection or external beam radiotherapy * No patients under 10 years old with embryonal rhabdomyosarcoma * Adequate peripheral blood stem cells stored * At least 2,500,000 CD34+ cells/kg * No impending bone fracture or spinal cord compression PATIENT CHARACTERISTICS: Age: * 12 and over Performance status: * 0-2 Life expectancy: * At least 2 months Hematopoietic: * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 (transfusion independent) * Hemoglobin at least 10.0 g/dL (RBC transfusion allowed) Hepatic: * Bilirubin no greater than 1.5 times normal * SGOT no greater than 2.5 times normal Renal: * Radioisotope glomerular filtration rate, iothalamate clearance, or creatinine clearance at least 60 mL/min Other: * No uncontrolled infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Recovered from prior immunotherapy * At least 3 months since prior bone marrow or peripheral blood stem cell transplantation (6 months for total body irradiation conditioning) and recovered * At least 1 week since prior cytokines * No immunomodulators during and for at least 4 weeks after study * No concurrent cytokines Chemotherapy: * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered * No more than 3 prior systemic chemotherapy regimens * No systemic chemotherapy during and for at least 4 weeks after study Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * See Biologic therapy * Recovered from prior radiotherapy * No prior maximum tolerable radiotherapy (greater than 30 Gy) to the spinal cord * No prior therapeutic doses of bone-seeking radiopharmaceutical (e.g., samarium Sa 153 lexidronam pentasodium EDTMP) * No radiotherapy during and for at least 4 weeks after study * Local radiotherapy to any tumor site allowed provided at least 1 evaluable lesion is untreated Surgery: * See Disease Characteristics * No surgical resection of all bone metastases evaluable by PET during and for 1 month after study Other: * At least 4 weeks since prior bisphosphonates